Page last updated: 2024-10-22

am 580 and Cutaneous T-Cell Lymphoma

am 580 has been researched along with Cutaneous T-Cell Lymphoma in 1 studies

Am 580: a selctive retinoic acid receptor (alpha) agonist; structure given in first source
4-{[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)carbonyl]amino}benzoic acid : An amidobenzoic acid obtained by formal condensation of the carboxy group of (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzoic acid with the anilino group of 4-aminobenzoic acid. A selective RARalpha agonist.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wang, L1
DeMarco, SS1
Peaks, MS1
Maiorana-Boutilier, AL1
Chen, J1
Crouch, MJ1
Shewchuk, BM1
Shaikh, SR1
Phillips, CM1
Bridges, LC1

Other Studies

1 other study available for am 580 and Cutaneous T-Cell Lymphoma

ArticleYear
RARĪ±/RXR synergism potentiates retinoid responsiveness in cutaneous T-cell lymphoma cell lines.
    Experimental dermatology, 2017, Volume: 26, Issue:11

    Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Benzoates; Bexarotene; Cell Adhesion; Cel

2017